Tissue Regeneration Therapeutics Inc. (TRT) and Héma-Québec enter a definitive licensing agreement for the first human clinical trial of TXP-1

Toronto, Canada, June 2nd 2014: Tissue Regeneration Therapeutics Inc. (TRT) today
announced it has entered into a definitive licensing agreement with Héma-Québec
for the use of its patented mesenchymal stromal cell (MSC) technology TXP-1 for
use in a clinical trial for the treatment of Steroid-Refractory Acute Graft-versus-Host
Disease. Héma-Québec will be responsible for the manufacture of the TXP-1 product
in its cGMP facility and is partnering with the Centre de Cancérologie Charles
Bruneau – C.H.U. Sainte-Justine, for the coordination of the clinical trial.

TRT is a progressive biotechnology company with a focus on the commercial
development of our patented Human Umbilical Cord PeriVascular Cell (HUCPVC)
platform technology and product TXP-1. TRT has discovered the world’s richest
source of mesenchymal stromal cells (MSCs) with potent regenerative, angiogenic,
anti-inflammatory, and immuno-regulatory properties. Unique advantages of the
TRT HUCPVC platform technology are founded on the highly enriched source of
these important cells compared to other tissue sources. Specifically, HUCPVCs
represent high cell yields at harvest from tissue normally discarded at birth; high
frequencies of mesenchymal stromal cells within the harvested population, their
increased biological potential compared to cells derived from adult tissues and their
inexhaustible supply.

About TRT
TRT is a Canadian Controlled Private Corporation (CCPC) with a focus on the
commercial development of their patented Human Umbilical Cord PeriVascular Cell
(HUCPVC) platform technology product TXP-1. TRT is the first company in the world
to have issued and allowed patents in the USA, Europe and Australasia, for extraction
of these unique cells from umbilical cord tissue. TRT provides license opportunities
to collaborating partner companies in the family banking, regenerative medicine and
defense sectors. Additional information is available at

About Héma-Québec
Héma-Québec’s mission is to efficiently meet the needs of the Québec population
for safe, optimal-quality blood and blood products, human tissues, cord blood,
mother’s milk and cellular products; to develop and provide expertise and
specialized, innovative services in the field of human biological products. Additional
information is available at

Write a comment